Market revenue in 2023 | USD 6,469.8 million |
Market revenue in 2030 | USD 9,254.0 million |
Growth rate | 5.2% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.73% in 2023. Horizon Databook has segmented the Europe rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The Europe rheumatoid arthritis therapeutics market is substantially changing, influenced by healthcare reforms, research advancements, and patient-focused initiatives across different countries. The prevalence of RA is increasing due to an aging population and changing lifestyles, leading to a growing demand for effective & innovative treatment options across the continent.
Healthcare reforms in various European countries prioritize patient access to high-quality care and promote evidence-based treatments. These reforms encourage healthcare providers to explore and implement advanced RA therapies that offer patients improved outcomes and better quality of life.
The focus on evidence-based medicine drives the adoption of new and innovative treatment modalities, fostering a dynamic and evolving market landscape. Research and development in the field of rheumatoid arthritis are thriving across Europe, with a particular focus on biologic drugs and targeted therapies.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe rheumatoid arthritis therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Europe rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account